UnratedDrug recall · FDA · Published March 16, 2022
Dr. Reddy's Atorvastatin Tablets Recall: Impurities May Cause Harm
Dr. Reddy's recalls 80mg Atorvastatin Calcium tablets with impurities that could cause harm. Affected lots from India, expiring 2022-2023. Stop using and contact for details.
“Dr. Reddy's Atorvastatin Tablets Recall: Impurities May Cause Harm.” GovInfoNow, updated August 18, 2026. https://govinfonow.com/recall/35075-dr-reddy-s-atorvastatin-tablets-recall-impurities-may-cause-harm. Based on FDA recall #D-0726-2022 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0726-2022%22&limit=1).
The FDA announced on March 16, 2022, that Dr. Reddy's Laboratories, Inc. is recalling Atorvastatin Calcium Tablets, USP 80 mg due to failed impurity specifications. The recall affects 28,068 bottles distributed nationwide.
The FDA stated the hazard is failed impurities or degradation specifications, specifically out-of-specification results for related substances.
Context
GovInfoNow's records show Dr. Reddy's Laboratories, Inc. has had 85 other recalls on record since April 9, 2012. Other recent recalls of similar products include Dr. Reddy's Varenicline Tablets Recall (Nov. 11, 2025), Dr. Reddy's Succinylcholine Chloride Injection Recall (Sept. 26, 2025), and Dr. Reddy's Omeprazole Capsules Recall (June 30, 2025). Other recent recalls of similar products include Macleods Olanzapine Tablets 5mg Recall (Aug. 27, 2026), SUN PHARMACEUTICAL Clindamycin Phosphate Topical Solution Recall (Nov. 26, 2025), and Sagent Busulfan Injection Recall (May 4, 2026).
How to tell if you have this one
Check for lot numbers T000707, T000756, T000758, T000759 (expiring 03/2022) or T2100600, T2101075 (expiring 01/2023) or T2102802 (expiring 07/2023). The product is sold in India with NDC 55111-124-90.
Brand
Dr. Reddy's
Category
Drug
Based on the official FDA remedy
What to do — step by step
Check Product Lot Number
Look for lot numbers T000707, T000756, T000758, T000759 (expiring 03/2022), T2100600, T2101075 (expiring 01/2023), or T2102802 (expiring 07/2023) on the packaging.
Where it went and when
Where it was distributed
Distributed nationwide.
Nationwide
Not listed
FDA distribution: “Nationwide in the USA.” States read from FDA’s own wording; “not listed” means the notice does not name it.
Distributed nationwide.
Recall timeline
FDA terminated this recall 20 months after the firm started it.
1Firm started the recall
2FDA classified it Class III
3Published in FDA’s Enforcement Report
4FDA terminated the recall
Dates from the agency record only; steps without a date are left out.
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
Official source: FDA Recall #D-0726-2022 (March 16, 2022) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0726-2022 to see it in context.
Plain-language summary written by qwen3:4b on August 18, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.